Volume 22, Number 9—September 2016
Research
Feasibility of Using Convalescent Plasma Immunotherapy for MERS-CoV Infection, Saudi Arabia
Table 1
Characteristics of participants in a study for the feasibility of collecting convalescent plasma from persons who had been infected with or exposed to MERS-CoV, Saudi Arabia, July–October 2015*
Characteristic |
Value |
---|---|
Healthcare workers exposed to laboratory-confirmed MERS-CoV patients, N = 230 | |
Median age, y (Q1, Q3) | 35 (29, 42) |
Sex | |
M | 34 (14.8) |
F | 196 (85.2) |
Work-associated exposure | |
Intubation | 52 (22.6) |
Bronchoscopy | 22 (9.6) |
Tracheal suctioning or inhalation therapy | 72 (31.3) |
Patient care | 117 (50.9) |
Reported total duration of exposure† | |
<24 h | 66/199 (33.2) |
>24 h | 133/199 (66.8) |
Reported exposure intensity‡ | |
Mild | 108/200 (54.0) |
Moderate | 60/200 (30.0) |
Severe | 31/200 (15.5) |
Laboratory-confirmed MERS-CoV infection | 11 (4.8) |
ELISA-reactive serum sample | 4 (1.7) |
Median time from exposure to testing positive, d (Q1, Q3) |
381 (246, 485) |
Patients with suspected or laboratory-confirmed MERS-CoV infection, N = 196 | |
Median age, y (Q1, Q3) | 65 (49, 76) |
Sex | |
M | 97 (49.5) |
F | 99 (50.5) |
Hospitalization admission area | |
Intensive care unit | 11 (5.8) |
Emergency room | 183 (88.8) |
Ward | 2 (0.97) |
Laboratory-confirmed MERS-CoV infection | 5 (2.6) |
ELISA-reactive serum sample | 8 (4.1) |
Median time to testing positive, d (Q1, Q3) |
7 (4, 12) |
Household contacts of confirmed MERS-CoV patients, N = 17 | |
Median age (range), y | 37 (26, 46) |
Sex | |
M | 6 (35.3) |
F | 11 (64.7) |
Laboratory-confirmed MERS-CoV infection | 0 |
ELISA-reactive serum sample | 0 |
Median time to antibody testing, d (Q1, Q3) | 34 (34, 34) |
*Unless otherwise specified, data are no. (%). Q1 and Q3, quartiles 1 and 3, respectively; MERS-CoV, Middle East respiratory syndrome coronavirus.
†Data from a self-administered survey question answered by 199 healthcare workers.
‡Data from a self-administered survey question answered by 200 healthcare workers.
1This author is a member of ISARIC (the International Severe Acute Respiratory and Emerging Infection Consortium).